Zinter Nicolas, Ye Tao, Semaan Hanna, Fraulob Valérie, Plassard Damien, Krezel Wojciech
Institut de Génétique et de Biologie Moléculaire et Cellulaire, INSERM U1258, CNRS UMR 7104, Université de Strasbourg, Illkirch, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire, INSERM U1258, CNRS UMR 7104, Université de Strasbourg, Illkirch, France..
Neurobiol Dis. 2025 Aug;212:106943. doi: 10.1016/j.nbd.2025.106943. Epub 2025 May 13.
The mechanisms underlying detrimental effects of mutant Huntingtin on striatal dysfunction in Huntington's disease (HD) are not well understood. Although retinoic acid receptor beta (RARβ) emerged recently as one of the top regulators of transcriptionally downregulated genes in the striatum of HD patients and mouse models, its involvement in disease progression remains elusive. Here we challenged functional relevance of RARβ dysregulation in HD onset and progression. Using a series of genetic mouse models, we investigated whether genetically reduced Rarβ expression synergizes with disease- causing mutant huntingtin (mHTT) fragment in R6/1 mice to accelerate HD-like behavioral, cellular and molecular striatal deregulations. We report that genetically compromised Rarβ signaling accelerates onset of motor abnormalities in the R6/1 HD mouse model. Transcriptional profiling revealed that downregulation of Rarβ expression in Rarβ; R6/1 mice also accelerates transcriptional signature of disease progression and aging by emergence of a cluster of upregulated genes related to cell-cycle, stem cell maintenance and telencephalon development, contributing thereby to degradation of striatal cell-identity. Reactivation of proliferative activity in the neurogenic niche and development-related transcriptional programs in the striatum prompt an attempt of lineage infidelity in HD striatum which may lead as a consequence to disease-driving energy crisis, as suggested by downregulation of oxidative phosphorylation genes, a well-accepted correlate of HD physiopathology, and a metabolic condition required for maintenance of proliferative activity and differentiation but not compatible with high energetic demand of differentiated and active neurons. Overall, our data indicate that RARβ delays disease progression, perhaps by delaying aging process.
突变型亨廷顿蛋白对亨廷顿舞蹈病(HD)纹状体功能障碍产生有害影响的潜在机制尚未完全明确。尽管视黄酸受体β(RARβ)最近被发现是HD患者和小鼠模型纹状体中转录下调基因的主要调控因子之一,但其在疾病进展中的作用仍不清楚。在此,我们对RARβ失调在HD发病和进展中的功能相关性提出质疑。通过一系列基因小鼠模型,我们研究了基因敲低Rarβ表达是否会与R6/1小鼠中致病的突变型亨廷顿蛋白(mHTT)片段协同作用,以加速类似HD的行为、细胞和分子纹状体失调。我们报告称,基因受损的Rarβ信号传导会加速R6/1 HD小鼠模型中运动异常的发作。转录谱分析显示,Rarβ; R6/1小鼠中Rarβ表达的下调还会通过出现一组与细胞周期、干细胞维持和端脑发育相关的上调基因,加速疾病进展和衰老的转录特征,从而导致纹状体细胞特性的退化。神经源性小生境中增殖活性的重新激活以及纹状体中与发育相关的转录程序促使HD纹状体出现谱系不忠的尝试,这可能会导致疾病驱动的能量危机,氧化磷酸化基因的下调表明了这一点,氧化磷酸化基因下调是HD生理病理学中一个公认的关联因素,也是维持增殖活性和分化所需的代谢条件,但与分化和活跃神经元的高能量需求不兼容。总体而言,我们的数据表明,RARβ可能通过延缓衰老过程来延缓疾病进展。